Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 25Lymphoma 15Neutropenia 9Lymphoma, Large B-Cell, Diffuse 7Leukemia 7Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Lymphoma, Follicular 5Leukemia, Lymphocytic, Chronic, B-Cell 5Triple Negative Breast Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Hodgkin Disease 4Chemotherapy-induced Neutropenia 4Urinary Bladder Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Colorectal Neoplasms 3Burkitt Lymphoma 3Breast Neoplasms, Male 3Adenocarcinoma, Bronchiolo-Alveolar 3Adenocarcinoma of Lung 3Waldenstrom Macroglobulinemia 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2

Interventions

Radiotherapy 11Cisplatin 10Paclitaxel 9pembrolizumab 7Fluorouracil 7Oxaliplatin 6Irinotecan 6tislelizumab 5Cetuximab 5Docetaxel 4Radiation 3Nivolumab 3Leucovorin 3Carboplatin 3Capecitabine 3Neoadjuvant Therapy 2Immunohistochemistry 2Biopsy 210-propargyl-10-deazaaminopterin 2tremelimumab 1sitravatinib 1sintilimab 1regorafenib 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1oblimersen 1durvalumab 1cixutumumab 1adavosertib 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Esophageal Squamous Cell Carcinoma × pegfilgrastim × Clear all
NCT00069953 2017-02-17

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Radiation Therapy Oncology Group

Phase 2 Completed
43 enrolled 5 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡